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Abstract
Cardiovascular diseases and cancers are leading
causes of morbidity and mortality. Reducing dietary
saturated fat and replacing it with polyunsaturated fat
is still the main dietary strategy to prevent
cardiovascular diseases, although major flaws have
been reported in the analyses supporting this
approach. Recent studies introducing the concept of
myocardial preconditioning have opened new
avenues to understand the complex interplay
between the various lipids and the risk of
cardiovascular diseases. The optimal dietary fat profile
includes a low intake of both saturated and omega-6
fatty acids and a moderate intake of omega-3 fatty
acids. This profile is quite similar to the Mediterranean
diet. On the other hand, recent studies have found a
positive association between omega-6 and breast
cancer risk. In contrast, omega-3 fatty acids do have
anticancer properties. It has been shown that certain
(Mediterranean) polyphenols significantly increase the
endogenous synthesis of omega-3 whereas high
intake of omega-6 decreases it. Finally,
epidemiological studies suggest that a high omega-3
to omega-6 ratio may be the optimal strategy to
decrease breast cancer risk. Thus, the present high
intake of omega-6 in many countries is definitely not
the optimal strategy to prevent cardiovascular disease
and cancers. A moderate intake of plant and marine
omega-3 in the context of the traditional
Mediterranean diet (low in saturated and omega-6
fatty acids but high in plant monounsaturated fat)
appears to be the best approach to reduce the risk of
both cardiovascular diseases and cancers, in particular
breast cancer.
Introduction
Cardiovascular disease (CVD) is a leading cause of death
in most countries. Reducing saturated fatty acid (SFA)
intakes is still at the heart of dietary recommendations
to reduce CVD, mainly because of its effect on blood
cholesterol [1]. This view has recently been challenged.
First, a review of epidemiological studies failed to con-
clude that SFAs are associated with an increased risk of
CVD [2]. Second, the validity of meta-analyses of clinical
trials showing that CVD can be prevented by replacing
SFAs with polyunsaturated fatty acids (PUFAs) has been
questioned [3,4] because they omitted relevant trials
with unfavorable outcomes (selection bias) and included
others that were poorly designed (no randomization)
[5,6]. Third, it has been claimed that the effect of diet
on a single biomarker (such as plasma cholesterol) is
insufficient evidence to assess CVD risk [7]. Fourth, the
hypothetical protective effect of omega-6 PUFAs has
been said to be considerably exaggerated [8,9], because
of the failure to draw a line between the trials that
selectively increased omega-6 PUFAs and those that
substantially increased omega-3 PUFAs - known to
reduce CVD risk [10,11] - together with omega-6
PUFAs to replace SFAs [3,4]. Finally, clinical and epide-
miological studies exploring the dietary fat issue failed
to provide a clear biological understanding of the effect
of the various dietary fats on the risk of CVD.
There is one exception: the Mediterranean diet [12],
which is a complex interplay between the different series
of dietary lipids, including conjugated or non-conjugated
(animal or industrial) trans fatty acids, short-, medium-
and long-chain SFAs, various series - at least the omega-7
and omega-9 - of monounsaturated fatty acids, and the
various series of PUFAs, including omega-3 and omega-6
[12,13]. All these lipids and their interactions should be
taken into account when analyzing the effect of dietary fat
on CVD complications and mortality. Besides the Mediter-
ranean diet, this complexity makes the interpretation of
* Correspondence: michel.delorgeril@ujf-grenoble.fr
Laboratoire Cœur & Nutrition, TIMC-IMAG, Université Joseph Fourier-CNRS,
Faculté de Médecine, Grenoble, France
de Lorgeril and Salen BMC Medicine 2012, 10:50
http://www.biomedcentral.com/1741-7015/10/50
Metabolism, diet and disease
© 2012 de Lorgeril and Salen; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
epidemiological data very difficult and explains the cease-
less controversy about dietary fats and the risk of CVD.
However, recent studies in experimental nutrition using
the concept of myocardial preconditioning [14] have pro-
vided new and critical insights into the biological effects of
dietary fat on CVD complications and mortality.
Dietary fat, myocardial preconditioning and
cardiovascular disease
Preconditioning - that is, the ability of the myocardium to
withstand an ischemia-reperfusion injury - is a major con-
cept in cardiology [14]. The extent of cell death during
and after myocardial ischemia is actually the primary
determinant of the outcome of a heart attack. Ventricular
arrhythmia and cardiac pump failure are among the main
clinical complications that are prevented by the initiation
of myocardial preconditioning. Drug makers have failed to
identify pharmacological methods able to induce chronic
preconditioning [15]. In contrast, there are strong clinical
and experimental data suggesting that lifestyle - including
moderate alcohol drinking and physical exercise - is a
potent preconditioner [16,17]. Also, polyphenols present
in certain plants - and abundant in red wine - induce pre-
conditioning [18]. Although obtained in experimental con-
ditions, data regarding chronic myocardial preconditioning
as induced by lifestyle and nutrition are highly consistent
with our general clinical knowledge regarding the effects
of lifestyle and nutrition on CVD complications and mor-
tality. The next question is whether myocardial precondi-
tioning could shed light on the role of dietary fat in CVD.
In fact, two recent studies on rat models have provided
major findings by comparing the effects of different dietary
fat profiles on the induction of myocardial preconditioning
[19,20]. In both studies, the investigators compared the
effects of diets that were high in SFAs or omega-6 but
poor in omega-3 with diets that were poor in SFAs and
omega-6 but rich in omega-3. In both studies, the best
protection was obtained in the groups of rats receiving the
diet high in omega-3 PUFAs but relatively poor in SFAs
and omega-6 PUFAs, while the diet rich in omega-6 but
relatively poor in SFAs and omega-3 PUFAs provided no
protection [19] or a protection halfway between the diets
rich in SFAs, on one hand, and in omega-3, on the other
hand [20]. Thus, as compared with the common Western
diet - rich in either SFAs or omega-6 PUFAs but poor in
omega-3 PUFAs - an optimal dietary pattern aimed at
reducing CVD complications and mortality should include
a reduced intake of both SFAs and omega-6, in addition to
increased plant and marine omega-3 PUFAs. Not surpris-
ingly, this dietary fatty acid profile is similar - but not
identical - to that of the Mediterranean diet, which also is
rich in plant monounsaturated fat and poor in industrial
trans fatty acids [12,13].
These data should help identify the optimal dietary
fatty acid profile to reduce the risk and the complica-
tions of CVD. Thus, maintaining high [8] or increasing -
as proposed by certain experts [6,9] - the intake of
omega-6 in lieu of SFAs is definitely not the optimal
strategy to prevent CVD complications.
Dietary fat and cancer
In animal studies, omega-6 PUFAs have a strong mam-
mary tumor-enhancing effect [21,22]. In order to exert
their carcinogenic effects, they must first undergo an
oxidative metabolization, mainly through the lipoxygenase
and cyclooxygenase pathways [23,24]. The main substrate
of these oxidative pathways is arachidonic acid, which is
mainly produced from dietary linoleic acid, the most com-
mon omega-6 PUFAs in Western foods and cooking fats.
Several recent epidemiologic studies have found a positive
association between dietary omega-6 PUFAs and breast
cancer risk [25-30]. Certain analyses took into account a
genetic predisposition related to omega-6 metabolism. To
determine whether 5-lipoxygenase (LOX)-mediated diet-
ary omega-6 metabolism might influence breast cancer
risk, investigators examined genetic variants of the LOX
enzyme in combination with linoleic acid intakes [25].
They found that women with a genetic aberration affecting
the LOX enzyme whose diet provided a high level of
omega-6 (linoleic acid) had a significantly increased breast
cancer risk [25]. However, when women with the same
high-risk genetic profile had a diet lower in linoleic acid,
their genotype had no significant effect on their breast
cancer risk. This demonstration that a diet-gene interac-
tion increases the risk of cancer may explain why some
previous studies were inconsistent or conflicting. Other
recent studies have shown interactions between heterocyc-
lic amines and omega-6 PUFAs on the one hand [26], and
between omega-3 and omega-6 on the other hand [27], in
determining the risk of invasive breast cancer. Other fac-
tors, such as the obesity status [28], were shown to affect
the association between dietary PUFAs and breast cancer
risk. Finally, the food sources of omega-3 and omega-6
PUFAs, as well as their relative amounts in the diet of
individuals, appear to be very important for breast cancer
risk [29,30].
Thus, there are several recent and concordant studies
that strongly suggest that dietary omega-6 PUFAs - the
consumption of which is encouraged worldwide to
decrease blood cholesterol - increase the risk of breast
cancers. In the same line of reasoning, it is important to
recall that the most frequently prescribed cholesterol-low-
ering drugs (including statins) increase the blood concen-
tration of arachidonic acid, the main omega-6 PUFA in
cell membranes [31]. Also, studies have suggested that low
cholesterol and/or cholesterol-lowering are associated
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with an increased risk of cancers [32]. Thus, despite the
fact that many confounders tend to obscure the effects of
cholesterol-lowering drugs on the clinical occurrence of
cancers, the association of high intake of omega-6 and sta-
tins - both aimed at reducing blood cholesterol to prevent
CVD - may add up to increase cancer risk, in particular
breast cancer risk. Further studies are urgently needed to
explore the issue.
It could be said that most data regarding the effects of
dietary omega-6 PUFAs on cancers are observational
[25-30] and do not demonstrate cause-effect relation-
ship. Only randomized trials can demonstrate causality.
In fact, two dietary trials not initially designed to test a
diet-cancer hypothesis, the Veterans Los Angeles trial
[33] and the Lyon Diet Heart Study [34], provided some
information about dietary omega-6 and cancers. In the
Los Angeles trial, there was a huge increase in dietary
omega-6 in the experimental group compared with the
control group (15% total energy versus 5%) and there
was a significant increase in the incidence of new can-
cers and in cancer mortality in the high omega-6 group
[33]. By contrast, in the Lyon trial, the intake of omega-
6 was slightly but significantly reduced in the experi-
mental group (3.6% total energy versus 5.3%) and there
was a significant decrease in cancer incidence in the low
omega-6 group [34]. These two trials with very different
amounts of omega-6 in the experimental groups do not
definitely demonstrate that omega-6 fatty acids per se
increase the risk of cancer - other dietary factors and
various interactions (including drug treatment as men-
tioned above) likely played a role in the clinical surfa-
cing of new cancers and their severity - but they clearly
signal that lipid profiles with high or relatively high (>
5% energy) omega-6 tend to increase the risk of cancers,
which is in line with the observational studies discussed
above.
At the same time, omega-3 PUFAs were shown to
have chemopreventive properties against various cancers
and their complications, including colon and breast can-
cer [35,36]. It is therefore important to design dietary
strategies that will result in increased omega-3 in diet,
blood and tissues, associated with decreased omega-6. In
addition to increasing the dietary intake of omega-3, it is
possible to stimulate the endogenous synthesis of very
long-chain omega-3 PUFAS - often called ‘marine’
omega-3 - out of their plant substrate alpha-linolenic
acid, through the consumption of plant pigments such
as the polyphenols found, for instance, in grapes and
red wine [37-39]. Both alpha-linolenic acid and the poly-
phenol anthocyanins are present in quite large amounts
in the traditional Mediterranean diet, also poor in
omega-6, which may at least partly explain the remark-
able protection this diet provides against cancers
[40,41]. In contrast, the main dietary omega-6 linoleic
acid inhibits synthesis and cell incorporation of long-
chain omega-3 PUFAs [42,43] which is in line with the
effects of omega-6 on cancer risk as discussed above.
The association of oleic acid - the main fatty acid of
olive oil, a major component of the Mediterranean diet
- with breast cancer risk has been analyzed in several
studies [44-46] and provided conflicting data. In fact, it
is only when the level of oleic acid in blood or cells was
used in the analyses (and not as a nutrient through a
frequency questionnaire) that it was positively associated
with cancer risk [46]. The level of oleic acid in blood
and tissue is more dependent on endogenous metabo-
lism than on dietary intake. The main enzymatic system
regulating oleic acid level is the delta-9 desaturase - also
called stearoyl-coenzyme A desaturase - and its activity
depends on dietary (carbohydrate intake), hormonal
(insulin) and lifestyle (physical exercise) factors [47].
Thus, blood concentration of oleic acid is not a surro-
gate of the consumption of oleic acid but rather a bio-
marker of lifestyle associated with insulin resistance,
which is by itself positively associated with the risk of
breast cancer [48]. Finally, dietary oleic acid is not
necessarily a marker of olive oil consumption as it is
also one of the main fatty acids of meat. It is critical in
epidemiologic studies analyzing the relationships
between oleic acid intake and any clinical outcome to
include the geographic area of the studied population: in
the Mediterranean area, the dietary source of oleic acid
is mainly olive oil (a plant food) whereas in most Wes-
tern countries, animal foods are the main sources of
oleic acid. Importantly, olive oils contain more than the
sole lipids; certain phytonutrients such as polyphenols
may also interfere with the risk of cancers [49]. Thus,
when analyzing the relationships between breast cancer
and dietary habits, the type of fatty foods - plant versus
animal - is as important as the type of fatty acids.
Summary and prospects
From the most recent experimental and epidemiological
studies, we conclude that the optimal dietary fat pattern
to reduce the risk of both CVD and most cancers
should include a low intake of SFAs and omega-6
PUFAs. Small amounts (1% to 2% of energy intake) of
the essential linoleic acid - easy to find in most Western
foods - are sufficient to prevent omega-6 deficiency
[50,51]. The amounts of omega-6 in most Western
foods are so high that it could be difficult to obtain an
intake of omega-6 lower than 4% of energy [52], which
would probably be the optimal level. The high average
intake of omega-6 PUFAs in Western countries [53,54]
may explain the persistently high rate of CVD complica-
tions and the increased incidence of certain cancers,
including breast cancer. The intake of omega-3 PUFAs,
from plant and marine sources, should be moderate (a
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minimum of 3 g/day in average for an adult with at least
2 g/day of the essential alpha-linolenic acid), which is far
from the case at present in many populations [53,54].
Finally, regarding the intake of oleic acid, it is critical
to differentiate the food sources, since the health effects
of oleic acid obtained from meat or from olive oil are
different. To simplify the dietary advice aimed at pro-
tecting health - and help consumers to understand it -
the best approach is probably the traditional Mediterra-
nean diet model. No dietary pattern has been so exten-
sively studied, and no other has been shown to provide
so many benefits without any adverse effects.
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